

Oral Submucous Fibrosis: A Progressive Debilitating Oral Web Disease

Abhilash. R. Krishnan¹ and Jayakrishnan²

¹ Sri Sankara Dental College, Kerala University

Received: 15 December 2013 Accepted: 4 January 2014 Published: 15 January 2014

Abstract

Amongst the list of pre-malignant conditions, Oral Submucous Fibrosis (OSMF) forms one of the most debilitating diseases of the oral cavity. It is predominantly seen among populations using betel quid, indicating areca nut as the most conspicuous agent in the etiological agents. A clear dose-dependent relationship in relation to both the duration and frequency of chewing areca nut was revealed, although other risk factors such as excessive use of chilies and spices and malnutrition were also put forth. Research in some aspects in the background of progressive fibrosis associated with the disease, has allowed to put light onto the mechanisms involved in the malignant transformation to the most prevalent, potentially malignant oral disorder in south Asia. Reduction in matrix metalloproteinases (MMP's) and increased secretion of tissue inhibitors of MMP's play the most significant role in collagen accumulation whilst fibrogenic cytokines, mainly TGF- β over expression leading to increased production of collagen. There is increasing incidence of the disease and subsequent malignant transformation. Hence the article focuses to review the etiology, pathogenesis, clinical features and management of OSMF.

Index terms— areca nut, fibrous bands, betel quid, vesicles, burning sensation, reduced mouth opening, marbled appearance, hyaluronidase.

1 Introduction

On the basis of clinical and histopathological findings, Pindborg defined Oral Submucous Fibrosis as "an insidious chronic disease affecting any part of the oral cavity and sometimes the pharynx. Although occasionally preceded by and or associated with vesicle formation, it is always associated with a juxta epithelial inflammatory reaction followed by a fibro elastic change of the lamina propria with epithelial atrophy leading to stiffness of the oral mucosa and causing trismus and inability to eat".

It is a slow, progressive fibrotic disease causing fibroelastic change and inflammation in the oral mucosa, leading to inability to open the mouth, swallow or speak 1,2 . This was accredited to the accumulation of inelastic fibrous tissue in the juxta epithelial region of the oral mucosa, along with concomitant muscle degeneration 3 . The most common site to be involved was found to be the buccal mucosa, although other parts of the oral cavity were also found to involve, including the pharynx 4 .

These reactions may be the result of direct stimulation from exogenous antigens like Areca alkaloids or changes in the tissue antigenicity that may lead to an autoimmune response.

2 II.

3 Epidemiology

Most common prevalence was found among the Indians, ranging from 0.2% to 1.2%. A survey revealed an overall prevalence of up to 4% in Kerala 5 . Amongst the reported cases 0.5% was found to be in women 6 . The

42 reason for the rapid increase of the disease is reported to be due to an upsurge in the popularity of commercially
43 available areca nut in south asia 7 .

44 III.

4 Etiology and Pathophysiology

46 The etiology of OSMF is still not fully unwinded. It is considered to be a multifactorial disease. According to
47 Liao, the areca nut in betel quid plays a major role in the pathogenesis of OSMF 8 . There was no significant
48 evidence to relate the habits of smoking or alcohol consumption alone in the pathogenesis of the disease 9,10 .
49 Arecoline, an active alkaloid found in betel quid, stimulates fibroblasts to increase production of collagen by 150%
50 11 . Chung-Hung in 2006, studied that arecoline was found to elevate mRNA and protein expression of cystatin
51 C, a non glycosylated basic protein consistently upregulated fibrotic diseases, in a dose dependent manner in
52 persons with OSMF 12 .

53 Yet another hypothesis grips on the fact that, the high copper content of areca nut acts as an initiating factor
54 in OSMF. This was suggested by the fact that, soluble copper levels in oral fluids significantly increases after
55 chewing areca nut for 5-30 minutes 13 .

56 Other factors thought to cause OSMF include iron and vitamin B complex deficiency that derange the repair
57 of inflamed oral mucosa, leading to defective healing and resultant scarring. As a result, the oral mucosa becomes
58 more prone to the effects of areca nut and chilies.

59 The role of chilies and spices in the list of etiological agents is still a topic of debate among the scientific
60 community. It was shown that the capsaicin in chilies stimulates the widespread palatal fibrosis in rats 14 .
61 However, the incidence of OSMF was lower in Genetics is believed to play a role in OSMF patients, which
62 leads to immune system changes. People without the betel nut chewing and chilly ingestion were reported to
63 have OSMF 16 . Mutations in APC gene and low expression of wild type TP 53 tumor suppressor gene in
64 affected patients, increased the risk of malignant transformation 17 .The increase in CD4 cells with HLA-DR in
65 OSMF tissues suggest that lymphocytes are activated and number of langerhans cells increased. The presence of
66 these immunocompetent cells and with increased CD4 to CD8 ratio in OSMF tissue, suggest an ongoing cellular
67 immune response resulting in imbalance of immune regulation and an alteration in local tissue architecture.
68 These reactions can be from the direct stimulation from exogenous antigens or of changes in tissue antigenicity
69 that leads to an autoimmune response 18 . Increased levels of proinflammatory cytokines and reduced antifibrotic
70 interferon gamma (IFN-gamma) in patients with OSMF were demonstrated 19 .

71 IV.

5 Clinical Features

73 OSMF was found to be predominant in females 16 . The mean age was 43 years. Burning sensation and
74 discomfort in the oral mucosa during mastication was the most common complaint amongst the reported cases.
75 There is associated depapillation of the tongue (Fig: 1). Progressive changes including difficulty in mastication,
76 reduced salivation, dysphasia, pain in the ears and loss of auditory acuity due to stenosis of the pharyngeal end
77 of Eustachian tubes.

78 In advanced cases, the jaws become inseparable and totally inelastic and plastic and nutrition can be maintained
79 only by pushing the food into mouth. The buccal mucosa is frequently ulcerated and secondarily infected
80 consequent to ischemia and constant pressure of the mucosa against the buccal aspect of the teeth.

81 Pindborg provided staging criteria for OSMF 20 . He divided the stages according to the clinical presentation
82 of the disease as: Early lesions demonstrate blanching of oral mucosa and older lesions presents with vertical and
83 circular palpable fibrous bands in the buccal mucosa and around the mouth opening or lips, resulting in mottled,
84 marble like appearance(Fig: ??) of the mucosa.

85 This stage is characterized by reduced mouth opening, stiff and small tongue, fibrotic and depigmented gingiva,
86 shrunken bud like uvula.

87 Stage 3: speech and hearing deficits may occur as a part of the sequel. Histological examination reveals severely
88 atrophic epithelium with complete loss of rete ridges. Varying degrees of epithelial atypia may be present. The
89 underlying lamina propria exhibits severe hyalinization, with homogenization of collagen. Cellular elements and
90 blood vessels are greatly reduced 18 .

91 V.

6 Investigations

93 Clinical presentation of the disease plays an upper hand in the diagnosis phase. Other investigations include
94 complete hemogram, toluidine blue test, incisional biopsy and immune fluorescence tests 21 .

7 VI.

8 Management

97 The earlier the treatment begins, better it is for the patient. The treatment modes depend upon the state of the
98 disease at the time of presentation. If it is detected at a very early stage, cessation of the habit would provide

99 sufficient relief. But moderate to severe stages of OSMF are almost always irreversible. Usually the disease is
100 very resistant to treatment. The proposed treatment regimens aims hinder the progression of the disease process.
101 Submucosal injected steroids and hyaluronidase, placental extracts, oral iron preparations and topical vitamin A
102 and steroids are some the agents that have been used 22 . All of these therapies are usually palliative. Surgical
103 treatment includes simple excision of fibrotic bands, split thickness skin grafting following bilateral temporalis
104 myotomy or coronoidectomy 11 . The use of oral stent as an adjunct to surgery to prevent relapse of the fibrotic
105 bands has also been studied 23 . Other treatment modalities include administration of Antoxid OD for 6-8 weeks,
106 Lycopred OD for 6-8 weeks and physiotherapy for improving mouth opening 22 .

107 **9 VII.**

108 **10 Malignant Transformation**

109 OSMF is a well recognized potentially malignant disorder of the oral mucosa. Simultaneous occurrence of oral
110 leukoplakia and OSMF is demonstrated to carry a IX. higher risk for malignancy than with OSMF alone which
111 amounts from 4-13% 24 .

112 **11 Volume**

113 VIII.

114 **12 Conclusion**

115 The incidence of OSMF is on the rise with the popularity of commercially available betel nut products. It also
116 carries a significant morbidity rate from oral cancer. So it is desirable that OSMF is diagnosed as early as possible.
117 At best, it is palliate the symptoms of OSMF. In palliative care, the patient is the focus of treatment, not the
118 disease. A stepwise approach to OSMF management is advocated, with the level of entry into the treatment
119 algorithm being dictated by the disease severity and response to treatment. Although clinicians strive to achieve
120 lesion resolution and primary outcomes of therapies aims to concentrate on symptom reduction and improvement
121 of quality of life. Intervention studies and public health awareness programme linked with OSMF condition and
habits may prove the best way to control disease process at the root level.



1

Figure 1: Stage 1 :

122



1234

Figure 2: Figure 1 Figure 2 Figure 3 Figure 4



Figure 3:

123 2.

- 124 [Liao (2001)] *Adenomatoid polyposis coli gene mutation and decreased wild type p53 protein expression in oral*
125 *submucous fibrosis: a preliminary investigation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, P H
126 Liao . Aug 2001. 92 p. .
- 127 [Liao et al. (2001)] *Adenomatous polyposis coli gene mutation and decreased wildtype p53 protein expression in*
128 *oral submucous fibrosis: a preliminary investigation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, P
129 H Liao , T L Lee , L C Yang . Aug 2001. 92 p. .
- 130 [Haque et al. ()] 'An immunohistochemical study of oral submucous fibrosis'. M F Haque , M Harris , S Meghji
131 , P M Speight . *J Oral Pathol Med* 1997. 26 (2) p. .
- 132 [Seedat and Van Wyk (1988)] 'Betel-nut chewing and submucous fibrosis in Durban'. H A Seedat , C W Van
133 Wyk . *S Afr Med J* Dec 3 1988. 74 (11) p. .
- 134 [Ariyawardana et al. (2006)] 'Effect of betel chewing, tobacco smoking and alcohol consumption on oral
135 submucous fibrosis: A case-control study in Sri Lanka'. A Ariyawardana , A D Athukorala , A Arulanandam
136 . *J Oral Pathol Med* Apr 2006. 35 (4) p. .
- 137 [Ekanayaka and Carcinogene Mutagene ()] Titakararne Ekanayaka , Carcinogene Mutagene . *S5: oncogenomics*
138 *of head and neck*, 2013.
- 139 [electron microscopic study Arch Pathol (1960)] 'electron microscopic study'. *Arch Pathol* Aug 1960. 70 p. .
- 140 [Anoop and Priyanka] *House surgeon, Sri Sankara dental college Varkala*, . A Anoop , Priyanka . Trivandrum.
141 (dist.)
- 142 [Borle and Borde ()] 'management of oral submucous fibrosis: a conservative approach'. R M Borle , S R Borde
143 . *J Oral Maxillofac Surg* 1991. 49 (8) p. .
- 144 [Zain et al. ()] 'oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits: consensus
145 from a workshop held in Kuala Lumpur, Malaysia'. R B Zain , N Ikeda , P C Gupta . *J Oral Pathol Med*
146 November 25-27, 1996. 1999. 28 p. .
- 147 [Le ()] 'Oral Stent as treatment adjunct for oral submucous fibrosis'. P V Le , Gornitsky . *Oral Surg Med Oral*
148 *Pathol* 1996. 81 (2) p. .
- 149 [Shear et al. ()] 'Oral submucous fibrosis in South African Indians: an epidemiological study'. M Shear , J
150 Lemmer , I S Dockrat . *S Afr Med Sci* 1967. 32 p. .
- 151 [Haque et al. (2000)] 'Oral submucous fibrosis patients have altered levels of cytokine production'. M F Haque ,
152 S Meghji , U Khitab , M Harris . *J Oral Pathol Med* Mar 2000. 29 (3) p. .
- 153 [Sabharwal ()] 'Oral Submucous Fibrosis-A review'. R Sabharwal . *J Adv Med Dent Scie Res* 2013. 1 (1) p. .
- 154 [Ranganathan and Devi (2004)] 'Oral submucous fibrosis: A case control study in Chennai, South India'. K
155 Ranganathan , M U Devi , JoshuaE . *J Oral Pathol Med* May 2004. 33 (5) p. .
- 156 [Aziz ()] 'oral submucous fibrosis: an unusual disease'. S R Aziz . *J N J Dental Association* 1997. 68 p. .
- 157 [Rajendran ()] 'oral submucous fibrosis: etiology, pathogenesis and future research'. R Rajendran . *Bull World*
158 *Health Org* 1994. 72 (6) p. .
- 159 [Caniff et al. ()] 'Oral submucous fibrosis: its pathogenesis and management'. J P Caniff , W Harvey , M Harris
160 . *Br Dentl* 1986. 160 p. .
- 161 [Paissat DK, oral submucous fibrosis Int J Oral Surg ()] 'Paissat DK, oral submucous fibrosis'. *Int J Oral Surg*
162 1981. (10) p. .
- 163 [Pillai et al. (1992)] *Pathogenesis of oral submucous fibrosis. Relationship to risk factors associated with oral*
164 *cancer. Cancer*, R Pillai , P Balaram , K S Reddiar . Apr 15 1992. 69 p. .
- 165 [Pindborg et al. ()] 'Prevalence of oral sub mucous fibrosis among 50915 Indian villagers'. J J Pindborg , F S
166 Mehta , P C Gupta , D K Daftary . *BrJ Cancer* 1968. 22 p. .
- 167 [Pindborg and Mehta ()] 'Prevalence of oral submucous fibrosis among Indian villagers'. J J Pindborg , F S
168 Mehta . *Br J Cancer* 1968. 22 p. .
- 169 [Ieb ()] 'Progression of precancerous lesions to oral cancer'. Lian Ieb . *oral oncol* 2013. 49 p. .
- 170 [Trivedy et al. (2000)] 'Raised tissue copper levels in oral submucous fibrosis'. C R Trivedy , K A Warnakulasuriya
171 , T J Peters . *J Oral Pathol Med* Jul 2000. 29 (6) p. .
- 172 [Sirsat and Khanolkar] *Submucous fibrosis of the palate in diet preconditioned Wistar rats. Induction by local*
173 *painting of capsaicin—an optical and Govind. S.L and Indu Nambiar, House surgeon, Sri Sankara dental*
174 *college Varkala*, S M Sirsat , V R Khanolkar . Trivandrum. (dist.)
- 175 [Chung-Hung and Shun-Fa ()] 'The upregulation of cystatin C in oral submucous fibrosis'. T Chung-Hung , Y
176 Shun-Fa , Yu-Chao , C . *Oral Oncol* 2006. 24 p. .